Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections

Bibliography

• Janeway CA Jr. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci USA 2001;98(13):7461-8
   PubMed Web of Science ®Google Scholar
• Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012;13(3):214-22
   PubMed Web of Science ®Google Scholar
• Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60
   PubMed Web of Science ®Google Scholar
• Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132(4):296-305
   PubMedGoogle Scholar
• Stevenson M. HIV-1 pathogenesis. Nat Med 2003;9(7):853-60
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
   PubMed Web of Science ®Google Scholar
• Beutler B. Innate immune responses to microbial poisons: discovery and function of the Toll-like receptors. Annu Rev Pharmacol Toxicol 2003;43:609-28
   PubMed Web of Science ®Google Scholar
• Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 2007;76:141-65
   PubMed Web of Science ®Google Scholar
• Guha C, Mohan S, Roy-Chowdhury N, Roy-Chowdhury J. Cell culture and animal models of viral hepatitis. Part I: hepatitis B. Lab Anim (NY) 2004;33(7):37-46
   PubMed Web of Science ®Google Scholar
• Chayama K, Hayes CN, Hiraga N, Animal model for study of human hepatitis viruses. J Gastroenterol Hepatol 2011;26(1):13-18
   PubMed Web of Science ®Google Scholar
• Bissig KD, Wieland SF, Tran P, Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2011;120(3):924-30
   Web of Science ®Google Scholar
• Dandri M, Lutgehetmann M, Volz T, Petersen J. Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin Liver Dis 2006;26(2):181-91
   PubMed Web of Science ®Google Scholar
• Kremsdorf D, Brezillon N. New animal models for hepatitis C viral infection and pathogenesis studies. World J Gastroenterol 2007;13(17):2427-35
   PubMed Web of Science ®Google Scholar
• Philip Meuleman GL-R. HCV animal models: a journey of more than 30 years. Viruses 2009;1(2):222-40
   PubMed Web of Science ®Google Scholar
• Sheehy P, Mullan B, Moreau I, In vitro replication models for the hepatitis C virus. J Viral Hepat 2007;14(1):2-10
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Paiardini M. Immunodeficiency lentiviral infections in natural and non-natural hosts. Blood 2011;118(4):847-54
   PubMed Web of Science ®Google Scholar
• Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. Virology 2011;411(2):344-54
   PubMed Web of Science ®Google Scholar
• Yang HC. Primary cell models of HIV latency. Curr Opin HIV AIDS 2011;6(1):62-7
   PubMedGoogle Scholar
• Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406(6797):782-7
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76
   PubMed Web of Science ®Google Scholar
• Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007;76:447-80
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130(6):1886-900
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4(7):499-511
   PubMed Web of Science ®Google Scholar
• Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med 2004;10(12 Suppl):S70-6
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359(14):1486-500
   PubMed Web of Science ®Google Scholar
• Stacey AR, Norris PJ, Qin L, Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009;83(8):3719-33
   PubMed Web of Science ®Google Scholar
• Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101(17):6669-74
   PubMed Web of Science ®Google Scholar
• Ait-goughoulte M LJ, Zoulim F, Durantel D. Innate antiviral immune responses to hepatitis B virus. Viruses 2010;2(7):1394-410
   PubMed Web of Science ®Google Scholar
• Lucifora J, Durantel D, Testoni B, Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2009;51(1):63-72
   Web of Science ®Google Scholar
• Hosel M, Quasdorff M, Wiegmann K, Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50(6):1773-82
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2011; doi:10.1136/gutjnl-2011-301073
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Skinner NA, Thompson AJ, Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45(1):102-10
   PubMed Web of Science ®Google Scholar
• Lang T, Lo C, Skinner N, The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011;55(4):762-9
   PubMed Web of Science ®Google Scholar
• Chen Z, Cheng Y, Xu Y, Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128(3):400-8
   PubMed Web of Science ®Google Scholar
• Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 2010;6(7):e1000986
   PubMed Web of Science ®Google Scholar
• Yu S, Chen J, Wu M, Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010;91(Pt 8):2080-90
   PubMedGoogle Scholar
• Wu J, Meng Z, Jiang M, Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49(4):1132-40
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13(17):2436-41
   PubMed Web of Science ®Google Scholar
• Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001;75(15):7059-66
   PubMed Web of Science ®Google Scholar
• Frese M, Pietschmann T, Moradpour D, Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 2001;82(Pt 4):723-33
   PubMedGoogle Scholar
• Sumpter R Jr, Loo YM, Foy E, Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005;79(5):2689-99
   PubMed Web of Science ®Google Scholar
• Wang N, Liang Y, Devaraj S, Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol 2009;83(19):9824-34
   PubMed Web of Science ®Google Scholar
• Breiman A, Grandvaux N, Lin R, Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 2005;79(7):3969-78
   PubMed Web of Science ®Google Scholar
• Li K, Foy E, Ferreon JC, Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005;102(8):2992-7
   PubMed Web of Science ®Google Scholar
• Lee J, Wu CC, Lee KJ, Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006;103(6):1828-33
   PubMed Web of Science ®Google Scholar
• Schott E, Witt H, Neumann K, A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 2007;47(2):203-11
   PubMed Web of Science ®Google Scholar
• Chang S, Kodys K, Szabo G. Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology 2009;51(1):35-42
   Web of Science ®Google Scholar
• WHO/UNAIDS/UNICEF. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector progress towards Universal Access Progress report 2011. World Health Organization, Switzerland, 2011
   Google Scholar
• Beignon AS, McKenna K, Skoberne M, Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005;115(11):3265-75
   PubMed Web of Science ®Google Scholar
• Meier A, Alter G, Frahm N, MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007;81(15):8180-91
   PubMed Web of Science ®Google Scholar
• Kamga I, Kahi S, Develioglu L, Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis 2005;192(2):303-10
   PubMed Web of Science ®Google Scholar
• Yan N, Lieberman J. Gaining a foothold: how HIV avoids innate immune recognition. Curr Opin Immunol 2011;23(1):21-8
   PubMed Web of Science ®Google Scholar
• Yan N, Regalado-Magdos AD, Stiggelbout B, The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010;11(11):1005-13
   PubMed Web of Science ®Google Scholar
• Yan N, Cherepanov P, Daigle JE, The SET Complex Acts as a Barrier to Autointegration of HIV-1. PLoS Pathog. 2009;5:e1000327
   PubMedGoogle Scholar
• Lester RT, Yao XD, Ball TB, Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS 2008;22(6):685-94
   PubMed Web of Science ®Google Scholar
• Wu J, Lu M, Meng Z, Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007;46(6):1769-78
   PubMed Web of Science ®Google Scholar
• Wu J, Meng Z, Jiang M, Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 2010;129(3):363-74
   PubMed Web of Science ®Google Scholar
• Preiss S, Thompson A, Chen X, Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 2008;15(12):888-900
   PubMed Web of Science ®Google Scholar
• Zhang X, Meng Z, Qiu S, Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell Microbiol 2009;11(11):1624-37
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Colledge D, Rodgers S, Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 2009;14(6):797-808
   PubMed Web of Science ®Google Scholar
• Guo H, Jiang D, Ma D, Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 2009;83(2):847-58
   PubMed Web of Science ®Google Scholar
• Li J, Lin S, Chen Q, Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol 2010;84(13):6387-99
   PubMed Web of Science ®Google Scholar
• Lu M, Lohrengel B, Hilken G, Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes. J Virol 2002;76(1):58-67
   PubMed Web of Science ®Google Scholar
• McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74(5):2255-64
   PubMed Web of Science ®Google Scholar
• Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79(11):7269-72
   PubMed Web of Science ®Google Scholar
• Chang WW, Su IJ, Lai MD, Toll-like receptor 4 plays an anti-HBV role in a murine model of acute hepatitis B virus expression. World J Gastroenterol 2005;11(42):6631-7
   PubMed Web of Science ®Google Scholar
• Menne S, Tennant BC, Liu KH, Anti-viral efficacy and induction of an antibody response against surface antigen with the tlr7 agonist gs-9620 in the woodchuck model of chronic HBV infection. J Hepatol 2011;54(Suppl 1):S441
   Google Scholar
• Lanford RE, Guerra B, Chavez DC, Therapeutic efficacy of a TLR7 Agonist for HBV chronic infection in chimpanzees. J Hepatol 2011;54(Suppl 1):S45
   Google Scholar
• Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007;12(1-2):80-7
   PubMed Web of Science ®Google Scholar
• Evans JT, Cluff CW, Johnson DA, Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003;2(2):219-29
   PubMedGoogle Scholar
• Dupont J, Altclas J, Lepetic A, A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 2006;24(49-50):7167-74
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13(5):552-9
   PubMed Web of Science ®Google Scholar
• Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 2008;9(3):137-45
   PubMed Web of Science ®Google Scholar
• Sablan BP, Kim DJ, Barzaga NG, Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012;30(16):2689-96
   PubMed Web of Science ®Google Scholar
• Cooper C, Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 2011;10(4):417-27
   PubMed Web of Science ®Google Scholar
• Lohmann V, Korner F, Koch J, Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285(5424):110-13
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197(5):633-42
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Evans MJ, Syder AJ, Complete replication of hepatitis C virus in cell culture. Science 2005;309(5734):623-6
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T, Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11(7):791-6
   PubMed Web of Science ®Google Scholar
• Broering R, Wu J, Meng Z, Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48(6):914-22
   PubMed Web of Science ®Google Scholar
• Wang B, Trippler M, Pei R, Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J Hepatol 2009;51(6):1037-45
   PubMed Web of Science ®Google Scholar
• Meuleman P, Libbrecht L, De Vos R, Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005;41(4):847-56
   PubMed Web of Science ®Google Scholar
• Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007;104(51):20507-11
   PubMed Web of Science ®Google Scholar
• Azuma H, Paulk N, Ranade A, Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007;25(8):903-10
   PubMed Web of Science ®Google Scholar
• Dandri M, Burda MR, Torok E, Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33(4):981-8
   PubMed Web of Science ®Google Scholar
• Mercer DF, Schiller DE, Elliott JF, Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7(8):927-33
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Guyader D, Patton H, Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007;47(2):174-82
   PubMed Web of Science ®Google Scholar
• Jones HM, Chan PL, Graaf PH, Webster R. Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C. Br J Clin Pharmacol 2012;73(1):77-92
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Berg T, Desager JP, Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005;42(3):724-31
   PubMed Web of Science ®Google Scholar
• Bigger CB, Guerra B, Brasky KM, Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78(24):13779-92
   PubMed Web of Science ®Google Scholar
• Helbig KJ, Lau DT, Semendric L, Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005;42(3):702-10
   PubMed Web of Science ®Google Scholar
• Gale M Jr, Blakely CM, Kwieciszewski B, Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998;18(9):5208-18
   PubMed Web of Science ®Google Scholar
• Taylor DR, Puig M, Darnell ME, New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol 2005;79(10):6291-8
   PubMed Web of Science ®Google Scholar
• Silverman RH. Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action. J Interferon Res 1994;14(3):101-4
   PubMedGoogle Scholar
• Hui DJ, Bhasker CR, Merrick WC, Sen GC. Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2.GTP.Met-tRNAi. J Biol Chem 2003;278(41):39477-82
   PubMed Web of Science ®Google Scholar
• Suzuki F, Arase Y, Suzuki Y, Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004;11(3):271-6
   PubMed Web of Science ®Google Scholar
• Sato K, Ishikawa T, Okumura A, Expression of Toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2007;22(10):1627-32
   PubMed Web of Science ®Google Scholar
• Caron G, Duluc D, Fremaux I, Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005;175(3):1551-7
   PubMed Web of Science ®Google Scholar
• Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 2006;176(5):2888-95
   PubMed Web of Science ®Google Scholar
• Schlaepfer E, Speck RF. TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-alpha. J Immunol 2011;186(7):4314-24
   PubMed Web of Science ®Google Scholar
• Scheller C, Ullrich A, McPherson K, CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004;279(21):21897-902
   PubMed Web of Science ®Google Scholar
• Trapp S, Derby NR, Singer R, Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol 2009;83(2):884-95
   PubMed Web of Science ®Google Scholar
• Olbrich AR, Schimmer S, Dittmer U. Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J Virol 2003;77(19):10658-62
   PubMed Web of Science ®Google Scholar
• Kabat D. Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol 1989;148:1-42
   PubMed Web of Science ®Google Scholar
• Wang Y, Abel K, Lantz K, The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 2005;79(22):14355-70
   PubMed Web of Science ®Google Scholar
• Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007;4(3):289-94
   PubMedGoogle Scholar
• Gibbert K, Dietze KK, Zelinskyy G, Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J Immunol 2010;185(10):6179-89
   PubMed Web of Science ®Google Scholar
• Olbrich AR, Schimmer S, Heeg K, Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol 2002;76(22):11397-404
   PubMed Web of Science ®Google Scholar
• Miyazawa M, Nishio J, Chesebro B. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol 1992;66(7):4497-507
   PubMed Web of Science ®Google Scholar
• Teleshova N, Kenney J, Jones J, CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells. J Immunol 2004;173(3):1647-57
   PubMed Web of Science ®Google Scholar
• Teleshova N, Kenney J, Williams V, CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques. J Leukoc Biol 2006;79(2):257-67
   PubMed Web of Science ®Google Scholar
• Vagenas P, Aravantinou M, Williams VG, A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One 2010;5(9):e12891
   PubMedGoogle Scholar
• Fujimoto C, Nakagawa Y, Ohara K, Takahashi H. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol 2004;16(1):55-63
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K, HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005;102(42):15190-4
   PubMed Web of Science ®Google Scholar
• Zhu Q, Egelston C, Gagnon S, Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010;120(2):607-16
   PubMed Web of Science ®Google Scholar
• Wang Y, Blozis SA, Lederman M, Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol 2009;16(4):499-505
   PubMed Web of Science ®Google Scholar
• Abel K, Wang Y, Fritts L, Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol 2005;12(5):606-21
   PubMedGoogle Scholar
• Kraft AR, Krux F, Schimmer S, CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood 2007;109(7):2982-4
   PubMed Web of Science ®Google Scholar
• Rehli M. Of mice and men: species variations of toll-like receptor expression. Trends Immunol 2002;23(8):375-8
   PubMed Web of Science ®Google Scholar
• Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002;99(21):13825-30
   PubMed Web of Science ®Google Scholar
• Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 2006;103(47):17862-7
   PubMed Web of Science ®Google Scholar
• Lin YJ, Huang LR, Yang HC, Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci USA 2010;107(20):9340-5
   PubMed Web of Science ®Google Scholar
• Dorner M, Horwitz JA, Robbins JB, A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474(7350):208-11
   PubMed Web of Science ®Google Scholar
• Berges BK, Rowan MR. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 2011;8:65
   PubMed Web of Science ®Google Scholar
• Available from: http://www.hemispherx.ne
   Google Scholar
• Available from: http://www.3m.com/pharma/
   Google Scholar
• Available from: http://www.iderapharma.com
   Google Scholar